Product finder
StemMACS™ Small Molecules
Find out more about our growing range of small molecule activators and inhibitors here.
January 1, 2018

REAlease MicroBead Kits, human

Maximal flexibility with our releasable MicroBeads and antibody fragments for positive cell isolation from PBMCs.

December 2, 2017

Tumor-Associated Fibroblast Isolation Kit

Isolate tissue-derived, tumor-associated fibroblasts from dissociated mouse tumors.

December 1, 2017

Classical Monocyte Isolation Kit

Our solution for the fastest untouched isolation of CD14+CD16– monocytes from human PBMCs.

November 1, 2017

Cancer coaching for the immune system

Novel cell therapy will teach immune cells how to fight cancer

February 1, 2018

Krebs Nachhilfe für das Immunsystem

Neuartige Zelltherapie soll Immunzellen in der Krebsabwehr schulen

February 1, 2018
Cell separation – faster and more reliable than ever

New: The MultiMACS™ X raises fully automated, walk-away, high-throughput cell separation to a new level

November 2, 2017

New: MACSQuant® X revolutionizes high-throughput flow cytometry

Miltenyi Biotec is launching a new era in the field of fully automated high-throughput flow cytometry analysis: Now up to 384-well plates can be handled in less than 60 minutes giving users fast, reliable, and reproducible results. This is made possible by the MACSQuant® X – a benchtop instrument that gives you all the flexibility and is easy to use.

September 14, 2017
CAR-TCR Summit Europe
London, United-Kingdom - February 20-22,
BMT Tandem Meetings
Salt Lake City, UT, USA - February 21-25
EBMT 2018 - 44th Ann Meeting of the Eur Society for Blood and Marrow Transplantation
Lisbon, Portugal - March 18-21
E-ISFA 2nd Congress of the European Group
Vienna, Austria - March 22-24

Customer login

Go

Forgot password?
Register for account

0 Shopping cart

Contact

Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 877 591 1060
macs@miltenyibiotec.com
Contact overview

Product finder

Antibody panel builder

Toolbox

Loading...

Change country

Please select your country to continue